AOD-9604 is a synthetic 16-aa hGH fragment (residues 176–191; CAS 221231-10-3). Formula/mass anchors and lot COA purity panels. Research use only.
AOD-9604 is a synthetic 16-amino-acid fragment corresponding to residues 176–191 of the C-terminus of human growth hormone. It is a discrete research material with its own CAS, formula, molar mass, and lot documentation — not a catalogue nickname for every “hGH fragment” listing, and not a synonym for full-length growth hormone or unrelated GH-axis research SKUs.
If you found “aod-9604,” “aod 9604,” “aod-9604 research chemical,” “aod-9604 coa,” or “aod-9604 third party tested” in a listing, the useful questions are which registry fields the seller claims, whether the certificate matches those anchors, and how the vial lot is documented. Aliases vary; registry fields and certificates do not.
This page covers Peptide Foundry’s published identity anchors, the purity panels a research buyer should demand, a worked third-party lot for the live 5 mg option, and short pathway-class literacy — then soft-handoffs to the AOD-9604 research product page. Research use only.
Key points
- AOD-9604 = synthetic 16-amino-acid fragment corresponding to hGH residues 176–191 (C-terminus); supplied as lyophilized research material.
- Peptide Foundry catalog anchors (live PDP): CAS 221231-10-3, formula C78H123N23O23S2, molar mass 1815.08 g/mol — match certificate fields to these claims. Residue count is published; a letter sequence is not listed on the live PDP and is not invented here.
- SKU
PF-AOD-9604; live size option 5 mg lyophilized — match each vial to its own lot certificate (current worked example = FO108 / ILS).- Demand a lot-matched COA: HPLC purity with method/wavelength when stated, identity method, named laboratory, and preferably independent portal verify; “third-party tested” or “high purity” without lot + named lab is unfinished.
- Research use only — not for human or veterinary use; not a fat-loss, weight-loss, body-composition, or wellness consumer product.
What is AOD-9604?
AOD-9604 is a sixteen-residue synthetic fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191. Residue count is sixteen. The research material on this page is that defined fragment class with the published registry anchors below — not a crude tissue extract and not a brand stack.
A short historical note anchors naming only. Published work associated with Monash University researchers in the late 1990s examined whether a fragment of the growth hormone molecule could be studied in adipocyte and preclinical models for signaling pathways distinct from the glycemic and growth-promoting pathways associated with full-length HGH. That is origin and naming / pathway-class history — not a catalogue mechanism claim, not registry proof, and not a reason to treat every “hGH fragment” nickname as interchangeable.
Physical form on research listings is lyophilized solid. Peptide Foundry’s current catalog documents describe lyophilized powder under SKU PF-AOD-9604 at a 5 mg size option. Appearance is a handling observation — not a purity proof and not a substitute for HPLC or identity data on a certificate.
Market aliases include AOD-9604, AOD9604, AOD 9604, hGH 176–191 fragment, and Tyr-hGH-related naming in literature. Aliases help search and inventory. They are not identity proof until you have CAS, formula, molar mass, residue framing, and a lot-matched certificate that matches the vial in hand. The live Peptide Foundry PDP does not publish a one-letter sequence; this page follows that publication set and does not invent one.
Chemical identity anchors
Peptide Foundry publishes a fixed identity set for single-vial AOD-9604. The values below match the live catalog chemistry table at the time of writing. Confirm against the current product page if a lot or chemistry block rotates after publish.
Naming and length
Class: synthetic 16-amino-acid fragment corresponding to residues 176–191 of human growth hormone (C-terminus). SKU PF-AOD-9604; size option on the live listing at publish time: 5 mg lyophilized.
CAS, formula, and molar mass
| Field | Peptide Foundry catalog (live /product/aod-9604/) |
|---|---|
| CAS | 221231-10-3 |
| Formula | C78H123N23O23S2 |
| Molar mass | 1815.08 g/mol |
| Length / class | 16-amino-acid synthetic fragment (hGH residues 176–191) |
| SKU | PF-AOD-9604 |
| Form | Lyophilized |
| Size (live option) | 5 mg |
Market pages sometimes round mass differently, omit sulfur count, or recycle CAS strings across unrelated fragment nicknames. The practical rule is: match the vendor’s stated CAS + formula + molar mass + fragment framing to the lot COA, then prefer orthogonal identity (MS / HPLC-RTM) over the nickname alone.
What an AOD-9604 COA should show
A certificate of analysis is stronger when it is lot-specific, names the laboratory, states methods, and can be checked outside the supplier’s own site. For the full verification workflow — batch match, named lab, HPLC versus identity, biosafety panels, portal codes — see How to read a research-peptide COA.
Minimum research COA fields
- A lot / batch ID that matches the vial character for character
- Test or report date(s) and a named laboratory
- HPLC purity with method (and wavelength when stated — for example 214 nm)
- An identity method (MS and/or HPLC-RTM)
- Product name / composition consistent with the label and the vendor’s published anchors
“Third-party tested,” “high purity AOD-9604,” or “99%+” without a named lab and a lot number is an unfinished claim. A pretty PDF that cannot be tied to the vial in hand is documentation theater.
Stronger panels (when claimed)
When a full QC panel is present — the pattern on current Peptide Foundry ILS-tested lots — read these as separate analytical results:
- Mass-spectrometry or HPLC-RTM identity confirmation
- Net peptide content versus labeled mass when reported
- Heavy metals by ICP-MS against stated limits
- Sterility / no growth
- Endotoxin (for example USP <85> / LAL)
- Illicit-substance screen (for example fentanyl — not detected)
These describe composition and contamination panels for research documentation. They are not a safety-for-human-use claim, and they do not replace identity or purity.
Worked example — lot FO108 (5 mg)
As published on the current Peptide Foundry AOD-9604 listing at the time of writing for the 5 mg option:
| Field | Value |
|---|---|
| Lot | FO108 |
| Size | 5 mg |
| Laboratory | ILS Laboratories |
| Received | 07/16/2026 |
| Tested | 07/19/2026 |
| Purity | 99.49% (HPLC @ 214 nm) |
| Net peptide content | 5.13 mg |
| Identity | HPLC-RTM — Pass |
| Fentanyl screen | Not Detected |
| Heavy metals | Pass |
| Sterility | No Growth |
| Endotoxin | NMT 0.05 EU/mL |
| Access code | 8BMLN2TM |
Cite those figures as Peptide Foundry–published transparency for this lot — not a universal industry floor. Re-verify against the live product panel if the lot rotates after publish.
Three steps that travel with any lot, not just FO108:
- Match the lot number on the vial to the lot on the certificate.
- Confirm CAS, formula, and labeled mass against the certificate and the product label.
- Verify the access code on the issuing laboratory’s own portal (ILS for FO108: access code 8BMLN2TM) — not only by opening a PDF hosted by the supplier.
Portable vendor criteria beyond a single SKU: USA research-peptide vendor criteria.
Related research peers (soft handoffs)
Research catalogues sometimes co-browse GH-axis materials beside hGH-fragment listings. Co-browsing is inventory adjacency — not a synonym set and not a protocol for combining materials.
- TH9507 / tesamorelin research identity — live GH-axis research identity sibling; match each vial to its own CAS, formula, and lot certificate.
- How to read a research-peptide COA and USA research-peptide vendor criteria — same trust workflow.
- Lyophilized peptide reconstitution — general lab diluent literacy without AOD-9604 schedules.
Match each vial to its own registry fields and lot certificate. Shared catalogue adjacency is literacy — not a stack recommendation.
Pathway-class literacy (preclinical / in vitro framing only)
Mechanism language is useful here only as classification of experimental systems in published literature. It does not establish catalogue-product outcomes in people, and it does not convert a citation into a certificate. Keep this section shorter than identity and COA literacy. Do not treat paper titles as product-use claims.
| Literature class (examples) | Acceptable framing on this page | Not used as product framing |
|---|---|---|
| Lipolytic signaling in adipocyte / murine models | Examined in preclinical publications exploring lipolytic signaling endpoints in adipocyte models | Fat-loss, weight-loss, or body-composition product claims |
| Distinction from full-length HGH glycemic / growth pathways | Studied as a fragment whose published preclinical context is distinct from full-length HGH glycemic and growth-promoting pathways | “Safe HGH alternative,” GH therapy, or human endocrine replacement framing |
Obesity- and lipid-metabolism-adjacent titles that appear in wider SERPs sit outside the scope of this RUO identity page and are not summarized as product use. Keep pathway class attached to the source paper and the experimental system. Identity remains an analytical question answered by CAS, formula, fragment framing, and the lot COA.
Storage and lab handling (lyophilized)
Standard laboratory practice for lyophilized synthetic peptides applies:
- Storage. Sealed vials at −20°C, protected from light and moisture. Lyophilized material is substantially more stable than solution.
- Temperature excursions. Brief ambient exposure in transit is normal for lyophilized material. Return vials to −20°C on arrival.
- Freeze–thaw. Minimize repeated freeze–thaw.
- Traceability. Keep the lot number with the material — lot number ties a vial back to its certificate.
Assay-specific handling follows your institution’s SOPs. This page does not publish personal reconstitution schedules or solution-use protocols for AOD-9604. General lyophilized-material diluent literacy (without compound-specific schedules) lives at Lyophilized peptide reconstitution.
Common questions
What is AOD-9604’s CAS, formula, and mass?
CAS 221231-10-3; formula C78H123N23O23S2; molar mass 1815.08 g/mol; synthetic 16-amino-acid fragment corresponding to hGH residues 176–191. Peptide Foundry catalogs the material as SKU PF-AOD-9604 (5 mg lyophilized option at publish time). The live PDP does not publish a letter amino-acid sequence; prefer registry fields over listing nicknames.
Is AOD-9604 the same as AOD9604 / AOD 9604 / hGH 176–191?
Those strings are the same listing/alias family for this fragment class when CAS, formula, molar mass, and the lot certificate agree. Styling is not a second compound. Match registry fields and the vial lot — do not treat an alternate hyphenation as identity proof by itself.
What makes an AOD-9604 COA usable — and what does “third-party tested” require?
Lot match to the vial, a named laboratory, HPLC purity with method/wavelength when stated, an identity method (MS and/or HPLC-RTM), and preferably an independent portal verify path. Stronger documentation adds net peptide content, heavy metals, sterility, endotoxin, and illicit screens when claimed. Worked FO108 figures above — ILS Laboratories, HPLC 99.49% @ 214 nm, HPLC-RTM pass, net 5.13 mg, access code 8BMLN2TM — are an example of that pattern on Peptide Foundry’s live listing. Workflow detail: How to read a research-peptide COA.
Is this for fat loss, weight loss, body composition, or human use?
No. Peptide Foundry supplies AOD-9604 strictly for laboratory and research use by qualified researchers. Mentions of lipolytic signaling endpoints or distinctions from full-length HGH pathways in published preclinical literature are pathway-class context only — not product benefits and not human therapy. This page does not describe consumer finished goods, personal-use schedules, administration protocols, or stack recommendations. AOD-9604 here is not a drug, supplement, consumer finished good, or veterinary product, and not for use in people or animals.
For the current lot certificate and product specifications, see the AOD-9604 research product page. Related library reading: How to read a research-peptide COA, USA research-peptide vendor criteria, Lyophilized peptide reconstitution, and TH9507 research identity.
Research use only. Nothing on this page describes or implies use in humans or animals. Pathway-class mentions of lipolytic signaling endpoints or distinctions from full-length HGH pathways refer only to preclinical and in-vitro literature contexts and are not product outcomes.
